NASDAQ: $BCRX
A Milestone for HAE Patients
BioCryst Pharmaceuticals has reached a significant milestone in the management of Hereditary Angioedema (HAE). The U.S. Food and Drug Administration (FDA) has officially approved Orladeyo (berotralstat) 150 mg oral pellets. This approval provides a new, convenient treatment option for adults and adolescents aged 12 years and older looking to prevent HAE attacks.
Understanding the New Formulation
Orladeyo is a plasma kallikrein inhibitor designed for once-daily use. The introduction of the 150 mg oral pellet formulation offers flexibility for patients who may prefer an alternative to traditional capsule forms. It is specifically indicated for the prophylaxis of HAE attacks, helping patients manage their condition with a focus on ease of administration.
Key Highlights of the Approval
- Indication: Prevention of HAE attacks in adults and pediatric patients 12 years and older.
- Administration: Once-daily oral dosage, now available as oral pellets.
- Target Audience: Designed for adolescents and adults who require long-term preventative care for HAE.
- Mechanism: Acts as a plasma kallikrein inhibitor to reduce the frequency of painful swelling attacks.
What This Means for the Community
For those living with HAE, an inherited disorder characterized by recurrent episodes of severe swelling, having diverse delivery methods is essential for maintaining treatment adherence. This approval represents BioCryst’s ongoing commitment to improving the quality of life for the HAE community by providing effective, non-injectable preventative therapy options.
Always consult with your healthcare provider to determine if Orladeyo is the right treatment plan for your specific medical needs.
Source: Read More